About Lixte Biotechnology
Lixte Biotechnology (NASDAQ:LIXT) is a biotech company dedicated to developing innovative treatments for cancer. It is currently traded on the NASDAQ stock exchange under the ticker symbol LIXT. The company's operations focus on discovering and advancing a portfolio of compounds that promise to play significant roles in cancer therapy, notably by targeting pathways critical for the growth and survival of cancer cells. Their projects range from early-stage research to clinical development, with an emphasis on creating drugs that can improve outcomes for patients facing various types of cancer. Lixte Biotechnology’s objectives emphasize innovation in oncology drug development, with the ultimate goal of bringing new therapeutic options to market that can offer better efficacy and fewer side effects than existing treatments.
Snapshot
Operations
Products and/or services of Lixte Biotechnology
- Lead product LB-100, a small molecule for treating solid tumors and hematologic cancers.
- Collaboration on clinical trials for LB-100 in combination with traditional cancer therapies.
- Research into the mechanisms of action of protein phosphatase inhibitors for improved cancer treatments.
- Exploration of LB-100’s potential in enhancing the effectiveness of immunotherapies.
- Investigations into the genetic profiles that predict sensitivity to LB-100 for personalized cancer therapy.
Lixte Biotechnology executive team
- Mr. Bastiaan van der Baan M.Sc.Chief Scientific Officer
- Mr. Geordan G. PursgloveCEO, President & Chairman
- Mr. Peter M. StazzoneChief Financial Officer